FDA-Approved Cannabis-Derived Medications

Three cannabis-derived drugs have cleared the full FDA approval process — a fact that surprises people who assume the federal government and cannabis exist in completely separate universes. These medications occupy a precise legal and pharmacological niche: they are derived from or chemically related to cannabis compounds, rigorously tested through clinical trials, and regulated under federal law in ways that state-licensed medical marijuana programs are not. Understanding the difference between these approved drugs and broader medical cannabis access matters both for clinical decision-making and for navigating insurance coverage.

Definition and scope

The FDA has approved three distinct cannabis-related medications through its standard New Drug Application process. Two are synthetic cannabinoids — dronabinol (marketed as Marinol and Syndros) and nabilone (Cesamet) — and one is a plant-derived cannabidiol formulation: Epidiolex, manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals).

Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol, the principal psychoactive compound in cannabis. Nabilone is a synthetic cannabinoid that mimics THC's structure but is not chemically identical. Epidiolex is the first FDA-approved drug derived directly from the cannabis plant — specifically purified cannabidiol (CBD) extracted from Cannabis sativa — making it categorically different from the synthetic options. For a deeper look at how these individual compounds behave at the molecular level, the cannabinoids: THC and CBD explained page provides useful grounding.

None of these approvals constitute federal endorsement of whole-plant marijuana. The FDA's approval authority operates under the Federal Food, Drug, and Cosmetic Act, and each of these medications passed through Phase I, II, and III clinical trial requirements that unscheduled herbal cannabis has not undergone at the federal level. The regulatory context for medical marijuana is considerably more tangled than the FDA-approved drug pathway, which follows a well-defined federal lane.

How it works

Each approved medication targets the endocannabinoid system — the network of receptors, endogenous ligands, and metabolic enzymes distributed throughout the central nervous system, immune system, and peripheral tissues.

Dronabinol and nabilone both bind primarily to CB1 receptors in the brain, which accounts for their antiemetic and appetite-stimulating effects. The psychoactive component is real and dose-dependent — both carry Schedule II classification under the Controlled Substances Act, reflecting recognized medical utility alongside abuse potential. Dronabinol in its Syndros formulation (an oral solution) is Schedule II; the older Marinol capsule formulation is Schedule III.

Epidiolex works through a different mechanism. Cannabidiol has low binding affinity at CB1 and CB2 receptors and appears to exert its antiseizure effects through multiple pathways — including modulation of sodium channels and interaction with GPR55 receptors — though the precise mechanism remains an active area of research (FDA, Epidiolex prescribing information). Epidiolex was initially placed in Schedule V by the DEA in 2018 after FDA approval, the lowest-restriction schedule under the Controlled Substances Act.

Common scenarios

These three medications cover a narrow but meaningful set of clinical applications:

1. Chemotherapy-induced nausea and vomiting (CINV): Dronabinol and nabilone are both FDA-approved for CINV in patients who have not responded adequately to conventional antiemetics. This is the original approved indication for both drugs, dating to dronabinol's 1985 approval.
2. AIDS-related anorexia and weight loss: Dronabinol carries an additional FDA approval for appetite stimulation in patients with AIDS-related anorexia who have experienced significant weight loss — an indication directly relevant to cancer patients and wasting conditions.
3. Dravet syndrome and Lennox-Gastaut syndrome: Epidiolex is FDA-approved for seizures associated with both of these severe, treatment-resistant epilepsy syndromes, as well as for tuberous sclerosis complex. The clinical trials that supported approval showed statistically significant reductions in seizure frequency compared to placebo (GW Pharmaceuticals/Jazz Pharmaceuticals, NEJM-published trial data). The broader discussion of cannabis for seizure disorders is explored at medical marijuana for epilepsy and seizures.

Insurance coverage for these medications differs substantially from state medical marijuana programs. Because they hold FDA approval and are classified as pharmaceutical products, they are eligible for coverage under Medicare Part D and many commercial insurance plans — unlike whole-plant medical marijuana, which remains uncovered by most insurance due to federal scheduling.

Decision boundaries

The line between FDA-approved cannabis-derived drugs and state-program medical marijuana is not merely bureaucratic. It reflects fundamentally different evidence standards, manufacturing controls, and legal frameworks.

FDA-approved medications come with standardized dosing, pharmaceutical-grade purity specifications, and contraindication data derived from controlled trials. A 100 mg capsule of Marinol contains a known, consistent quantity of dronabinol. The same confidence about concentration is harder to establish across the varied delivery methods and strains available through dispensaries, where potency can vary meaningfully by batch and producer.

Clinicians who want to use cannabis-based pharmacotherapy within a fully federal-legal framework are limited to these three products. Patients seeking treatment for conditions outside these narrow approved indications — chronic pain, anxiety and PTSD, multiple sclerosis, or sleep disorders, among others — must look to state medical marijuana programs, because no FDA-approved cannabis-derived drug covers those conditions.

The drug interaction profile also differs by product: Epidiolex, for instance, has well-documented interactions with valproate and clobazam that are established in its prescribing label, while interaction data for whole-plant cannabis products is less systematically characterized. This is the clearest practical illustration of what pharmaceutical-grade approval actually purchases: not just legality, but pharmacological specificity and documented risk.